

**RESPIRATORY DISEASES****PAPER – II**

Time : 3 hours

Max. Marks : 100

RPD/D/17/D/42/II

**Important instructions:**

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

- |    |  |       |
|----|--|-------|
| 1. | a) Classification of COPD.   | 3+7   |
|    | b) Management of COPD exacerbation.                                  |       |
| 2. | a) Bronchial challenge testing                                       | 5+3+2 |
|    | b) Exhaled nitric oxide  |       |
|    | c) Sputum examination in asthma                                      |       |
| 3. | a) Extra pulmonary sarcoidosis                                       | 6+4   |
|    | b) Indications for treatment of sarcoidosis.                         |       |
| 4. | Diffuse alveolar haemorrhage: Differential diagnosis and management. | 4+6   |
| 5. | a) Diagnostic approach in pulmonary embolism.                        | 5+5   |
|    | b) Thrombolytic therapy in pulmonary embolism.                       |       |
| 6. | a) Diagnosis of granulomatosis with polyangiitis (GPA)               | 5+5   |
|    | b) Remission induction therapy in ANCA associated vasculitis.        |       |
| 7. | a) Etiology of secondary spontaneous pneumothorax.                   | 5+5   |
|    | b) Therapeutic options of primary spontaneous pneumothorax.          |       |
| 8. | a) Lung complication of thoracic radiotherapy.                       | 5+3+2 |
|    | b) Stereotactic body radiotherapy                                    |       |
|    | c) Ablative radiotherapy   |       |

**P.T.O.**

**RESPIRATORY DISEASES**

**PAPER – II**

- |     |  |     |
|-----|--|-----|
| 9.  | a) Risk factors for a complicated course or mortality in patients with community acquired pneumonia. | 5+5 |
|     | b) Initial empiric antimicrobial therapy in community acquired pneumonia.                            |     |
| 10. | a) Life cycle of Pneumocystis jiroveci.  | 4+6 |
|     | b) Treatment of Pneumocystis pneumonia.  |     |

\*\*\*\*\*

www.FirstRanker.com